Overview

A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin

Status:
Recruiting

Trial end date:
2025-10-27

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in participants with type 2 diabetes (T2D) with inadequate glycemic control using metformin. The study will last approximately 46 weeks.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Dapagliflozin